A red alert is flashing for UK PLC as one of its key economic engines—the life sciences sector—is sputtering and showing signs of imminent failure. The flight of major international companies and the cancellation of billions in investment are threatening to stall a critical driver of national growth and innovation.
The warning lights are impossible to ignore. A major component, MSD’s planned £1 billion research facility, has been ripped out. Eli Lilly has put its own expansion plans on hold, and Sanofi is deliberately downshifting its UK operations, cutting its clinical trial activity by half. These are signs of a system under catastrophic stress.
The engine trouble stems from a faulty fuel mix of government policies. The industry has been choked by a combination of low prices for its products, high taxes via the clawback system, and a lack of public investment in new medicines. An internal government dispute over how to fix the problem has led to a complete maintenance breakdown.
While the UK still has high-quality “raw materials” in the form of its scientific talent and research institutions, the commercial machinery needed to convert them into power is breaking down. A complete engine overhaul, involving radical and immediate policy reform, is now essential. Failure to act will see this vital economic engine seize up completely.
